Related Experiment Video

Updated: Jul 5, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Microsomal triglyceride transfer protein (MTP) -493G/T gene polymorphism contributes to fat liver accumulation in HCV

R Zampino1, D Ingrosso, E Durante-Mangoni

  • 1Departments of Internal Medicine and Hepatology, F Cedrangolo, Second University of Naples, Naples, Italy.

Journal of Viral Hepatitis
|May 17, 2008
PubMed
Abstract

Insights

Hepatitis C genotype 3 patients with a specific MTP gene variation (T allele) show increased fatty liver accumulation and fibrosis. This MTP-493 G/T polymorphism impacts liver disease progression in HCV genotype 3.

Area of Science:

  • Hepatology
  • Genetics
  • Virology

Background:

  • Microsomal triglyceride transfer protein (MTP) activity is crucial for lipoprotein assembly and secretion, and reduced MTP activity is linked to Hepatitis C Virus (HCV) related fatty liver disease (steatosis).
  • Host genetic factors may play a role in the development of steatosis in HCV patients.

Purpose of the Study:

  • To investigate the association between the MTP-493 G/T gene polymorphism and the development of fatty liver accumulation and fibrosis progression in patients with chronic Hepatitis C.
  • To explore the influence of MTP genotype on disease parameters in relation to HCV genotype.

Main Methods:

  • Genotyping for MTP-493 G/T polymorphism in 102 treatment-naïve patients with biopsy-proven chronic hepatitis C.
  • Evaluation of HCV RNA levels, HCV genotype, HOMA-IR, serum adiponectin, TNF-alpha, and serum lipid profiles.

Main Results:

  • HCV genotype 3 patients carrying the T allele of the MTP-493 G/T polymorphism exhibited significantly higher degrees of steatosis compared to GG genotype carriers (3.45 +/- 0.37 vs 1.30 +/- 0.45, P < 0.001).
  • MTP 'T' allele carriers also showed elevated HCV RNA serum levels (P < 0.01) and increased hepatic fibrosis (P < 0.001).
  • In HCV genotype 3 patients, lower levels of cholesterol, ApoB, HDL, and LDL were observed irrespective of MTP genotype. No associations were found between MTP gene polymorphism and parameters in non-3 HCV genotypes.

Conclusions:

  • The T allele of the MTP-493 G/T gene polymorphism is associated with an increased predisposition to severe fatty liver accumulation in patients infected with HCV genotype 3.
  • Host genetic background, specifically the MTP-493 G/T polymorphism, influences the severity of liver steatosis and fibrosis in HCV genotype 3 infection.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...